Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 6/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2393408 | 1.00 | LY96 (0.34) | LY96NFE2L2LMNAGAAMAPT | |
| SCHEMBL18954106 | 0.83 | KDM1A (0.31) | — | |
| SCHEMBL18954104 | 0.83 | KDM1A (0.31) | — | |
| SCHEMBL1293193 | 0.81 | LY96 (0.36) | LY96NFE2L2GAAMAPTHSD11B1 | |
| SCHEMBL1245999 | 0.81 | LY96 (0.36) | LY96NFE2L2GAAMAPTHSD11B1 | |
| SCHEMBL30749709 | 0.80 | LY96 (0.49) | LY96NFE2L2HSD11B1 | |
| SCHEMBL9261193 | 0.80 | LY96 (0.49) | LY96NFE2L2HSD11B1 | |
| SCHEMBL9261189 | 0.80 | LY96 (0.49) | LY96NFE2L2HSD11B1 | |
| SCHEMBL1293024 | 0.78 | NFE2L2 (0.41) | LY96NFE2L2MAPT | |
| SCHEMBL1293025 | 0.78 | NFE2L2 (0.41) | LY96NFE2L2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017602-B2 | N-(2-(2-(5-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethylamino)ethyl)-3-(phenethoxy)propanamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy | ASTRAZENECA AB (SE) | 2011-09-13 | — | — | US | disclosed |
| EP-2303873-A1 | BENZOXAZINONE DERIVATIVES ACTING AS BETA2-ADRENORECEPTOR AGONIST FOR THE TREATMENT OF RESPIRATORY DISORDERS | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | disclosed |
| US-20100105642-A1 | NOVEL COMPOUNDS 409 | ASTRAZENECA AB (SE) | 2010-04-29 | — | — | US | disclosed |
| WO-2009154557-A1 | BENZOXAZINONE DERIVATIVES ACTING AS BETA2-ADRENORECEPTOR AGONIST FOR THE TREATMENT OF RESPIRATORY DISORDERS | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105642-A1 | NOVEL COMPOUNDS 409 | GPR119, CYP4B1, CYP4A11 | LY96 3839/4885NFE2L2 1953/4885LMNA 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.